创新药“出海”进入新阶段的三点启示

Core Insights - In 2025, China's innovative pharmaceuticals are expected to experience explosive growth in overseas licensing, with total overseas licensing exceeding $130 billion. This trend continues into 2026, with companies like Rongchang Biologics achieving significant overseas licensing deals [1] Group 1: Transition in Business Model - The "going global" strategy for innovative drugs has shifted from selling individual products to selling capabilities. Chinese pharmaceutical companies are now recognized for their comprehensive R&D platforms and validated clinical development capabilities, rather than just individual drug rights [2] - This transition necessitates that Chinese companies build a complete innovation capability chain, distinguishing industry leaders from ordinary participants based on their systematic pharmaceutical innovation capabilities [2] Group 2: Shift to Source Innovation - Sustainable "going global" requires a fundamental shift in R&D logic from incremental improvements to providing "first-in-class" or "best-in-class" solutions for unmet clinical needs. Recent high-value transactions indicate that capital is increasingly concentrating on companies with genuine differentiated innovation capabilities [3] - Companies that successfully navigate challenging fields, such as Alzheimer's disease, are gaining international recognition, highlighting the importance of investing in complex biological mechanisms and unclear development paths [3] Group 3: Strategic Global Positioning - The strategy of Chinese innovative pharmaceutical companies has evolved from merely exporting products to establishing a global ecosystem. More transactions are adopting risk-sharing models, indicating a proactive approach to R&D and commercialization for long-term value distribution [4] - "Going global" also represents a strategic move to secure future technological influence. Chinese companies are demonstrating competitive R&D efficiency in emerging technology areas, such as antibody-drug conjugates and cell therapies, positioning themselves favorably in the global pharmaceutical landscape [4] - The total overseas licensing amount exceeding $130 billion signifies that the Chinese innovative pharmaceutical industry is now qualified to participate in top-tier global competition, with the real challenge lying in subsequent global clinical advancement and commercialization capabilities [4]